Stryker Co. (NYSE:SYK) Shares Purchased by Mar Vista Investment Partners LLC

Mar Vista Investment Partners LLC increased its position in shares of Stryker Co. (NYSE:SYK - Free Report) by 15.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 81,834 shares of the medical technology company's stock after purchasing an additional 11,155 shares during the period. Stryker accounts for approximately 2.0% of Mar Vista Investment Partners LLC's portfolio, making the stock its 26th largest position. Mar Vista Investment Partners LLC's holdings in Stryker were worth $29,464,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. J. W. Coons Advisors LLC raised its position in shares of Stryker by 0.7% during the 4th quarter. J. W. Coons Advisors LLC now owns 3,653 shares of the medical technology company's stock worth $1,315,000 after acquiring an additional 26 shares in the last quarter. Mascoma Wealth Management LLC raised its holdings in Stryker by 22.7% during the fourth quarter. Mascoma Wealth Management LLC now owns 146 shares of the medical technology company's stock worth $53,000 after purchasing an additional 27 shares in the last quarter. Opal Wealth Advisors LLC lifted its position in shares of Stryker by 1.6% during the 4th quarter. Opal Wealth Advisors LLC now owns 1,816 shares of the medical technology company's stock worth $654,000 after buying an additional 28 shares during the last quarter. Lindbrook Capital LLC boosted its holdings in shares of Stryker by 2.0% in the 4th quarter. Lindbrook Capital LLC now owns 1,407 shares of the medical technology company's stock valued at $507,000 after buying an additional 28 shares in the last quarter. Finally, Alhambra Investment Management LLC grew its position in shares of Stryker by 1.5% in the 4th quarter. Alhambra Investment Management LLC now owns 1,997 shares of the medical technology company's stock valued at $719,000 after buying an additional 29 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

SYK has been the subject of a number of research reports. Argus set a $450.00 price objective on shares of Stryker in a research note on Monday, February 3rd. StockNews.com cut Stryker from a "buy" rating to a "hold" rating in a research report on Thursday, March 6th. Royal Bank of Canada lifted their price target on Stryker from $425.00 to $435.00 and gave the stock an "outperform" rating in a research report on Wednesday, January 29th. Truist Financial increased their price objective on Stryker from $409.00 to $413.00 and gave the company a "hold" rating in a report on Thursday, January 30th. Finally, Canaccord Genuity Group lifted their target price on shares of Stryker from $420.00 to $435.00 and gave the company a "buy" rating in a report on Wednesday, January 29th. Five analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company's stock. According to MarketBeat, Stryker currently has an average rating of "Moderate Buy" and a consensus price target of $423.53.

Stryker Price Performance

Shares of SYK traded up $4.29 during trading hours on Friday, reaching $365.34. 1,462,555 shares of the company traded hands, compared to its average volume of 1,355,868. The stock has a fifty day simple moving average of $367.81 and a 200 day simple moving average of $373.16. Stryker Co. has a fifty-two week low of $314.93 and a fifty-two week high of $406.19. The stock has a market capitalization of $139.45 billion, a PE ratio of 47.08, a price-to-earnings-growth ratio of 2.93 and a beta of 0.93. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK - Get Free Report) last released its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter in the prior year, the firm earned $3.46 EPS. As a group, research analysts predict that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be paid a dividend of $0.84 per share. The ex-dividend date is Monday, March 31st. This represents a $3.36 annualized dividend and a yield of 0.92%. Stryker's dividend payout ratio is presently 43.30%.

Insider Transactions at Stryker

In related news, Director Ronda E. Stryker sold 201,392 shares of Stryker stock in a transaction on Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the transaction, the director now owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. The trade was a 5.24 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Allan C. Golston sold 2,458 shares of the stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the sale, the director now owns 14,895 shares of the company's stock, valued at approximately $5,705,827.65. This represents a 14.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 5.20% of the company's stock.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.